HCA HCA Healthcare, Inc.

Tenet Healthcare's stronger cash flow is fueling bigger buybacks, but growth investments and capital needs will test how sustainable its strategy is.

On September 22, BMO Capital analyst Sean Dodge initiated coverage of HCA Healthcare, Inc. (NYSE:HCA) with an Outperform rating and a $495 price target. The bullish initiation centers on HCA’s targeted capital investments in high-growth geographic markets backed by strong demographic tailwinds. Coupled with compounding efficiency gains from its ongoing “resiliency” program and digital transformation, […]

HCA's rising admissions and shorter hospital stays could help it meet growing patient demand while using existing capacity more efficiently.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.

CYH's volume growth faces pressure from softer elective procedures and payer mix, while a recovery in demand could help margins and cash flow.

THC's revenue growth persists despite softer surgical volumes, driven by higher revenue per case, acuity and favorable service mix.

HCA Healthcare's healthy volume growth faces payer-mix pressure, but cost controls, network expansion and Medicaid payments may support earnings growth.

HCA Healthcare (HCA) is back in focus after five affiliated Texas hospitals filed suit against Independence Blue Cross, alleging more than $345,000 in unpaid claims between 2022 and 2024. At a share price of US$438.12, HCA Healthcare has seen a 2.85% 1 day share price return and a 12.99% 90 day share price return. Total shareholder return of 7.73% over one year and 80.41% over three years points to momentum that has built over time, even as the year to date share price return is down 6.86%,...

MD posts 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, aided by stronger reimbursement and acquisitions.

Despite a $2.8B settlement over BlueCard program disputes, five HCA-affiliated hospitals say the program still traps them in red tape.

ResMed (NYSE:RMD) outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Chairman and Chief Executive Officer Mick Farrell sai

HCA Healthcare, Inc. (NYSE:HCA) announced on September 15 that it had completed its acquisition of The College of Health Care Professions. The institution serves more than 8,000 students annually through 10 Texas campuses and online programs, offering more than 20 accredited healthcare programs. For HCA Healthcare, Inc. (NYSE:HCA), the opportunity is to connect education more […]

HCA Healthcare (NYSE:HCA) CFO Mike Marks said the hospital operator is navigating a changing policy environment in 2026 while continuing to see solid underlying demand for services outside of the health insurance exchanges. Speaking at an investor conference, Marks described the expiration of enhan

Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]

Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) President and CTO Nicolas Loebel spoke with Proactive's Stephen Gunnion about the company's photodisinfection technology, top-line results from its pivotal phase III LANTERN trial, and the commercial opportunity for Steriwave. The 5,188-patient phase III LANTERN study, conducted across 18 major US and Canadian hospitals, showed a 40.5% lower risk of 30-day surgical site infections. Loebel said the findings "change the entire nature of the company," highlighting a favourable safety profile with no device-related serious adverse events. He discussed the significance of 14 HCA Healthcare hospitals participating in the trial and the potential pathway to the US market. Steriwave remains investigational in the US and subject to FDA approval, with Ondine planning to take the full data package forward to the FDA, having already secured Fast Track and Qualified Infectious Disease Product designations. Loebel also outlined Ondine's commercial activities outside the US and the broader potential for photodisinfection in areas including intensive care, describing a recurring-revenue model combining reusable light devices with patient-specific consumables, with growth potentially coming from both new hospital adoption and increased treatments within each hospital. For more interviews and company updates, visit Proactive’s YouTube channel. Give the video a like, subscribe to the channel and enable notifications so you don’t miss future content. Read Proactive's Editorial Policy here: https://www.proactiveinvestors.co.uk/pages/editorialPolicy #OndineBiomedical #StereoWave #LANTERNTrial #Phase3Trial #SurgicalSiteInfections #InfectionPrevention #PhotoDisinfection #AntimicrobialResistance #HealthcareTechnology #MedTech #FDA #ClinicalTrials #HospitalInfections #HealthcareInnovation #Biotech #Investing #InvestorNews #ProactiveInvestors

CVS Health noted a continuation of "high-trend" medical cost growth at a Wells Fargo investor conference on Wednesday, helping to put a spring in the step of hospital stocks including HCA Healthcare, while souring the mood of managed care investors. Shares of CVS stock came away relatively unscathed, while UnitedHealth slipped and Oscar Health stumbled. CVS management's comments about medical cost trends were brief and vague, while Wells Fargo conference presentations by HCA and Universal Health Services didn't appear to provide updates to Q3 trends since Q2 earnings calls.

HCA Healthcare's (HCA) management delivered a consistent message around second-half cadence expectat

HCA Healthcare recently cut its full-year 2026 earnings guidance, citing a worsening payer mix after Affordable Care Act subsidy expirations, softer high-margin elective surgeries, and rising costs that also prompted targeted corporate and support-function layoffs and at least one hospital divestiture. These actions, alongside an estimated US$400 million quarterly revenue impact from payer shifts and an ongoing legal review of prior disclosures, highlight how policy-driven reimbursement...

Pomerantz Law Firm has launched an investigation into potential securities fraud and unlawful business practices at HCA Healthcare (NYSE:HCA). The probe focuses on whether HCA Healthcare and certain executives misled investors or breached fiduciary duties. The investigation could lead to future legal claims on behalf of shareholders depending on its findings. This kind of legal scrutiny highlights broader questions about risk, disclosure and income reliability across the healthcare sector...

HCA Healthcare (HCA) shares remain under pressure after the company cut its 2026 profit guidance, citing a weaker payer mix that reduced quarterly revenue by about $400 million and triggered fresh investor scrutiny. Against that backdrop, HCA Healthcare’s recent share price moves have been choppy, with a 1 day share price return of 1.78% after the guidance cut, a 90 day share price return of 9.96%, and a year to date share price decline of 13.01% at a last close of US$409.20. The 3 year total...

Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HCA Healthcare has underperformed the Nasdaq over the past year, but analysts are cautiously optimistic about the stock’s prospects.

First Eagle Investment Management, an investment management company, released its Q2 2026 investor update for “First Eagle Global Fund”. The letter can be downloaded here. Easing tensions in the Middle East led to a strong rally in risk markets in Q2. The S&P 500 Index rose 15.2%, while the MSCI EAFE Index gained 10.8%. Growth […]

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.

HCA Healthcare's resiliency program is helping control costs amid payer pressures, potentially supporting long-term profitability and EBITDA growth.

Despite trailing the broader market over the past year, HCA Healthcare continues to command a moderately optimistic outlook from Wall Street analysts, who see room for further upside in the stock.

UHS' 21% YTD slide has cheapened its valuation, but weaker volumes, ACA pressure and lower growth forecasts keep risks elevated.

Palantir Stock Rises as Fresh AI Demand Keeps Post-Earnings Momentum Alive

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.6% gain over the past six months, beating the S&P 500 by 11.4 percentage points.

THC's hospital growth is fueling earnings momentum as stronger volumes, revenues and margins help offset exchange weakness.

HCA Healthcare’s stock price has taken a beating over the past six months, shedding 24.5% of its value and falling to $404.01 per share. This might have investors contemplating their next move.

HCA Healthcare, Inc. (NYSE:HCA) reported its second-quarter 2026 financial results on July 24, confirming the figures previewed earlier in the month. While top-line growth remained healthy, a visible deterioration in payer mix and a revision to full-year profitability guidance triggered immediate target cuts across Wall Street. In its Q2 results, HCA Healthcare, Inc. reported that […]

HCA Healthcare (NYSE:HCA) is facing nationwide union led protests as workers press for higher wages and improved staffing during ongoing contract negotiations. Union organizers say demonstrations span multiple HCA Healthcare facilities across the US and focus on pay, staffing ratios, and working conditions. The dispute centers on how HCA Healthcare allocates resources, including reported profits and share buybacks, relative to frontline labor costs and staffing levels. These protests...

HCA Healthcare has appointed Michael Schlosser, M.D., as executive vice president and chief clinical officer and created a new Ambulatory Operations Group led by Charles Gressle, consolidating oversight of clinical services, digital transformation, and more than 2,700 outpatient facilities as part of a broad leadership realignment that began taking effect in 2026. An interesting angle for investors is that Schlosser will simultaneously run HCA’s Clinical Services Group and its digital...

Bill Rutherford, who served on the finance team of the Tennessee-based healthcare giant for decades, reflects on his career in health as he switches to board service in retirement.

ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share rose 16% to $2.95, while the company expanded gross margin despite continued inflation in electroni

Outset Medical (NASDAQ:OM) reported second-quarter 2026 revenue of $31.6 million, up 1% from a year earlier and 14% sequentially, as the dialysis technology company cited commercial progress, improving margins and a new $40 million refresh agreement with HCA Healthcare. Chair and Chief Executive Of

Don't let their recent poor performances chase you away.

The hospital juggernaut is adding Texas MedClinic’s locations to its nationwide portfolio of urgent care clinics amid rising consumer demand for fast and convenient medical attention.

HCA Healthcare delivered solid results in the second quarter, with revenue and earnings per share both ahead of Wall Street expectations. The positive market reaction reflected management’s ability to navigate significant headwinds, particularly an unexpected increase in uninsured patient volumes following the expiration of enhanced premium tax credits. CEO Samuel N. Hazen highlighted that while overall patient demand remained robust—especially for emergency services—unfavorable payer mix shifts

July 29 () - GE HealthCare on Wednesday beat Wall Street estimates for second-quarter profit, helped by strong demand for its ‌diagnostic and imaging devices and refunds of tariffs imposed under U. Shares of the medical device maker rose 12% in premarket trading.

HCA Healthcare (HCA), the United States' largest hospital chain, beat Wall Street on both revenue and profit for the second quarter, then watched its own stock fall anyway. The reason sits inside a single line item: a roughly $400 million pre-tax hit tied to patients losing health insurance ...

THC raised its 2026 outlook after Q2 earnings and revenues beat expectations, driven by strong same-facility growth and disciplined expense management.

HCA Healthcare's (HCA) Q2 results were largely in line with the company's pre-release but Health Ins

People formerly covered by the ACA exchanges are remaining uninsured almost on a one for one basis. “For us, obviously, it’s not a good thing,” CEO Sam Hazen said.

Independent monitors flagged recurring non-compliance issues tied to HCA Healthcare's acquisition of Mission Health for a third consecutive year. Concerns include discontinued industrial rehabilitation services, reduced access to services at Mission Hospital and affiliated facilities, and a Medicare termination notice. The findings focus attention on operational, regulatory, and reputational risks for NYSE:HCA as it manages this acquired network. HCA Healthcare, one of the largest for...

Moby summary of HCA Healthcare, Inc.'s Q2 2026 earnings call

A number of stocks fell in the morning session after concerns grew over a rising number of uninsured patients. The trend was highlighted in HCA Healthcare's recent earnings report, which pointed to a 'negative payer mix shift.' This term refers to a change in the types of insurance patients have, in this case, an increase in uninsured individuals resulting from losses in health insurance exchange coverage. For HCA, this shift was significant, reducing pre-tax income by an estimated $400 million

Despite strong earnings growth and strategic investments, HCA Healthcare Inc (HCA) faces headwinds from payer mix shifts and declining elective surgeries.

HCA Healthcare (NYSE:HCA) said its second-quarter performance reflected solid demand in several service lines and 11% growth in diluted earnings per share, but the company faced increased financial pressure as patients losing health insurance exchange coverage shifted largely into the uninsured popu